Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo

European Journal of Clinical Pharmacology

Volumn 62, Issue 7, 2006, Pages 539-546

  Wennerholm, Agneta ^a   Nordmark, Anna ^b   Pihlsgård, Maria ^a   Mahindi, Margarita ^a   Bertilsson, Leif ^a   Gustafsson, Lars L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Amodiaquine; CYP2C9; CYP2D6; Debrisoquine; Desethylamodiaquine; Losartan

Indexed keywords

AMODIAQUINE; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DEBRISOQUINE; DEETHYLAMODIAQUINE; KOFFEIN RECIP; LOSARTAN; LOSARTAN POTASSIUM; LOSEC MUPS; OMEPRAZOLE;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SWEDEN; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; AMODIAQUINE; ANTIHYPERTENSIVE AGENTS; ANTIMALARIALS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CONFIDENCE INTERVALS; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; DRUG INTERACTIONS; HUMANS; LOSARTAN; MIDDLE AGED; PHENOTYPE; TIME FACTORS;

EID: 33745727111     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0121-3     Document Type: Article

References (37)

1. WHO (2000) WHO expert committee on malaria. WHO Tech Rep Series 892:1-74
2. World Health Report 2001 WHO (2001)
3. Kitua AY (1999) Antimalarial drug policy: making systematic change. Lancet 354(Suppl):SIV32
4. WHO (2001) WHO/CDS/RBM/2001.35, WHO. Antimalarial drug combination therapy. Report of a WHO technical consultation
5. EANMAT (2003) The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health 8:860-867
6. Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, Garner P, Brasseur P (1996) Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348:1196-1201
7. Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM (2001) Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 29:30-35
8. Makanjuola RO, Dixon PA, Oforah E (1988) Effects of antimalarial agents on plasma levels of chlorpromazine and its metabolites in schizophrenic patients. Trop Geogr Med 40:31-33
9. Muralidharan G, Cooper JK, Hawes EM, Korchinski ED, Midha KK (1996) Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. Eur J Clin Pharmacol 50:121-128
10. Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yasar U, Bertilsson L (2003) The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73:517-528
11. Minzi OM, Rais M, Svensson JO, Gustafsson LL, Ericsson O (2003) High-performance liquid chromatographic method for determination of amodiaquine, chloroquine and their monodesethyl metabolites in biological samples. J Chromatogr B Anal Technol Biomed Life Sci 783:473-480
12. Svensson JO, Bertilsson L (1999) Rapid high-performance liquid chromatographic method for determination of debrisoquine and 4-hydroxy-debrisoquine in urine for CYP2D6 phenotyping. Pharmacogenetics 9:529-531
13. Lagerstrom PO, Persson BA (1984) Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 309:347-356
14. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358-363
15. Ritter MA, Furtek CI, Lo MW (1997) An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal 15:1021-1029
16. Yasar U, Dahl ML, Christensen M, Eliasson E (2002) Intraindividual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol 54:183-185
17. Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML, Bertilsson L (2002) Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 71:141-152
18. Wennerholm A, Johansson I, Massele AY, Jande M, Alm C, Aden-Abdi Y, Dahl ML, Ingelman-Sundberg M, Bertilsson L, Gustafsson LL (1999) Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics 9:707-714
19. Wennerholm A, Dandara C, Sayi J, Svensson JO, Abdi YA, Ingelman-Sundberg M, Bertilsson L, Hasler J, Gustafsson LL (2002) The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 71:77-88
20. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422
21. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254:628-631
22. Winstanley P, Edwards G, Orme M, Breckenridge A (1987) The disposition of amodiaquine in man after oral administration: effect of dose size on amodiaquine pharmacokinetics after oral administration. Br J Clin Pharmacol 23:1-7
23. Pussard E, Verdier F, Faurisson F, Scherrmann JM, Le Bras J, Blayo MC (1987) Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. Eur J Clin Pharmacol 33:409-414
24. Yue QY, Zhong ZH, Tybring G, Dalen P, Dahl ML, Bertilsson L, Sjoqvist F (1998) Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 64:384-390
25. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, Eichelbaum M (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15-26
26. Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M (1999) Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 9:715-723
27. Farrell GC (1987) Drug metabolism in extrahepatic diseases. Pharmacol Ther 35:375-404
28. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A (1993) Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44:707-715
29. Phillips-Howard PA, West LJ (1990) Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med 83:82-85
30. Baune B, Furlan V, Taburet AM, Farinotti R (1999) Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes. Drug Metab Dispos 27:565-568
31. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727
32. Kenworthy KE, Clarke SE, Andrews J, Houston JB (2001) Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 29:1644-1651
33. Nebert DW, Jorge-Nebert LF (2002) Pharmacognetics and pharmacogenomics. In: Rimoin DL, Connor JM, Pyeritz RE, Korf BR (eds) Emery and Rimoin's principles and practice of medical genetics, 4th edn. Harcourt Brace, Edinburgh, pp 590-631
34. NEDLIT (1991) Standard Treatment Guidelines and the National Essential Drugs List for Tanzania (NEDLIT), Ministry of Health, United Republic of Tanzania
35. Adedoyin A, Frye RF, Mauro K, Branch RA (1998) Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. Br J Clin Pharmacol 46:215-219
36. Steiner E, Dumont E, Spina E, Dahlqvist R (1988) Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther 43:577-581
37. Simooya OO, Sijumbil G, Lennard MS, Tucker GT (1998) Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol 45:315-317